ALSO NOTED: Quest Diagnostics buys HemoCue; Affymax pockets $10M milestone;Pozen to file response on Trexima; and much more...

> Quest Diagnostics has acquired Sweden's HemoCue, from the private equity firm EQT II for $420 million in cash. Release

> Affymax has nailed a $10 million milestone payment from Takeda. Release

> The FDA has called MGI Pharma's ad for a brain cancer drug "misleading." Report

> Pozen says it will file a response to the FDA on its Trexima migraine therapy in a few days. Report

> Aastrom has received an orphan drug designation for its Tissue Repair Cells used in chronic heart disease. Release

> Targacept is expanding its lab and office space in the Piedmont Triad Research Park. Release

> Generex is launching a Phase II trial for a breast cancer therapy. Release

> Heart muscle created from embryonic stem cells. Report

> New allergy vaccine works in a matter of weeks. Report

And Finally… A major new study concludes that fine grit in the air is a serious health threat to women, raising the risk of cardiovascular disease. Article

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.